Here's Why You Should Retain DaVita Stock in Your Portfolio for Now

DaVita shares are up 58.5% year to date, supported by stronger treatment volumes, first-quarter 2026 execution and increased full-year guidance. Its Integrated Kidney Care risk-based population rose to 64,900 in Q2 from 62,600 in Q1, representing roughly $5.8 billion of annualized medical spend, while U.S. dialysis delivered 7.23 million treatments at $415.90 revenue per treatment. Offsetting the growth outlook, management expects approximately $40 million of ACA and payer-mix headwinds in 2026 and $70 million in 2027; Q3 consensus calls for $3.53 billion in revenue, up 3.2% year over year, and EPS of $3.78, up 50.6%.

Analysis

DVA’s upside now depends less on treatment-count momentum and more on whether it can convert earlier-stage CKD management into durable medical-cost savings. In risk arrangements, incremental enrollment can initially dilute margins through care-management expense and adverse patient selection before shared-savings economics emerge; the payer, particularly HUM, captures much of the near-term benefit. The important underwriting variable is therefore IKC medical-cost trend versus benchmark—not membership growth alone—and this will likely become visible over the next 2-4 quarters.

After a sharp year-to-date rerating with consensus EPS unchanged recently, DVA is vulnerable to multiple compression if reimbursement-per-treatment weakens faster than volume growth offsets it. Commercial mix is a disproportionately large determinant of EBITDA, so even modest mix deterioration can matter more than apparently strong operating volume. FMS is not automatically the clean short leg: its distinct geographic, FX and restructuring exposures can swamp U.S. dialysis fundamentals; a DVA/FMS pair should only be used with tight factor controls.

The contrarian interpretation is that DVA’s push upstream may cannibalize its most economically attractive downstream dialysis treatments if successful at delaying ESKD onset. Long-term enterprise value can still rise if shared savings and patient retention compensate, but the market may be assigning too immediate a margin benefit to a model whose proof point requires multi-year cohort outcomes. Regulatory clarity around Medicare Advantage risk adjustment, Medicaid eligibility and dialysis reimbursement remains the principal asymmetric downside over the next 6-18 months.

Key Decisions for Investors

• Do not add directional DVA exposure following the rerating; maintain only a watch position until the next earnings release discloses revenue-per-treatment, commercial mix and IKC medical-cost performance. A guidance cut or a sequential decline in dialysis operating margin would falsify the near-term bull case.
• For healthcare-services relative value, consider a small long DVA / short FMS pair over a 3-6 month horizon only if DVA demonstrates stable commercial mix and IKC cost savings. Target relative outperformance from superior U.S. execution; exit if DVA’s reimbursement-per-treatment declines materially or FMS delivers a restructuring-driven margin inflection.
• Monitor HUM’s Medicare Advantage commentary and medical-loss-ratio trend as a read-through on the economic value of kidney-care partnerships. Improving HUM MLR without evidence of DVA shared-savings realization would argue that payer economics, rather than provider economics, are capturing the benefit and would be a reason to reduce DVA.
• Set a policy alert for CMS dialysis reimbursement proposals and Medicare Advantage risk-adjustment changes over the next 6-12 months. Any adverse proposal warrants hedging DVA through reduced gross exposure rather than options until implied-volatility and liquidity data are reviewed.